An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

Overview of attention for article published in Frontiers in immunology, February 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 51,011 followers.

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial https://t.co/79lgnDzAAd https://t.co/357CEYgqQ3

28 Feb 2023

Reply Repost Favourite

New Research: An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial: Introduction Arginase-1 (ARG1) and Programed death ligand-1 (PD-L1) play a vital role in immunosuppression… https://t.co/X

23 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.